Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAXIMISE trial of secukinumab for axial manifestations of psoriatic arthritis
MOH_2017-02-20_000131Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in psoriatic arthritis (PsA) and psoriatic spondylitis (3 arms), sponsored by Novartis. Primary endpoint: ASAS20 response at week 12. Started Nov 2016; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriatic arthritis (PsA)psoriatic spondylitis
Beyond the preview
Go deeper on MOH_2017-02-20_000131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-02-20_000131.